The global dermatology CRO market size accounted for USD 4.48 billion in 2024, grew to USD 4.75 billion in 2025 and is predicted to surpass around USD 8.09 billion by 2034, representing a healthy CAGR of 6.10% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Dermatology CRO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Dermatology CRO Market, by Service, 2024-2034
8.1.1 Project Management/Clinical Supply Management
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Data Management
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Regulatory/Medical Affairs
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Regulatory/Medical Affairs
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Clinical Monitoring
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Quality Management/Assurance
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Bio-statistics
8.1.7.1. Market Revenue and Forecast (2021-2034)
8.1.8. Investigator Payments
8.1.8.1. Market Revenue and Forecast (2021-2034)
8.1.9. Laboratory
8.1.9.1. Market Revenue and Forecast (2021-2034)
8.1.10. Clinical Monitoring
8.1.10.1. Market Revenue and Forecast (2021-2034)
8.1.11. Technology
8.1.11.1. Market Revenue and Forecast (2021-2034)
8.1.12. Clinical Monitoring
8.1.12.1. Market Revenue and Forecast (2021-2034)
8.1.13. Others
8.1.13.1. Market Revenue and Forecast (2021-2034)
9.1. Dermatology CRO Market, by Type, 2024-2034
9.1.1. Drug Discovery
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Preclinical
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Clinical
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. Dermatology CRO Market, by Phase Type, 2024-2034
10.1.1. Phase I
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Phase II
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Phase III
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Phase IV
10.1.4.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Service (2021-2034)
11.1.2. Market Revenue and Forecast, by Type (2021-2034)
11.1.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Service (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Service (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Service (2021-2034)
11.2.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Service (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Service (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Service (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Service (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Service (2021-2034)
11.3.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Service (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Service (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Service (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Service (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Service (2021-2034)
11.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Service (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Service (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Service (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Service (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Service (2021-2034)
11.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.5.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Service (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Phase Type (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Service (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Phase Type (2021-2034)
12.1. IQVIA HOLDINGS INC.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Covance Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Pharmaceutical Product Development, LLC (PPD)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Parexel International Corporation
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Charles River Laboratories International, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Icon, Plc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Medidata Solutions, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Syneos Health
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Pharmaron
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. GVK Biosciences Private Limited
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample